Methods: Between January 2005 and April 2019, 843 TA procedures were performed during 51 pregnancies in 43 patients: 745 plasma exchange sessions and 98 immunosuppression sessions. TA was performed in 29 (57%) pregnancies of 21 (48.8%) patients with antiphospholipid antibody syndrome (APS), in 20 (39.2%) pregnancies of 20 (46.5%) patients with congenital heart block (CHB), in 1 (1.9%) pregnancy of 1 (2.3%) patient with systemic sclerosis (SSc) and 1 (1.9%) pregnancy of 1 (2.3%) patient affected by lupic nephritis (SLE).

Results: During the period considered, apheresis sessions applied to pregnant women were 71% of the total (n = 13,251). The average age at the first treatment was 33 years (range 24-43). The mean management age at the first apheresic treatment was 21 weeks (range 4-32). Twelve (14%) apheresis sessions were complicated by adverse events, none required or prolonged hospitalization. There were 44 (86.3%) live births, 3 (5.9%) spontaneous abortions and 2 (3.9%) voluntary terminations of pregnancy (VT). In 29 (80.6%) patients the average gestational age at birth was 35 weeks (range 24-37) and cesarean section was performed in 41 (80.4%) cases. TA was added to conventional therapy in 24/29 (82.7%) patients with APS, to the detection of fetal cardiac activity, while in 5/26 (17.3%) it was introduced when the first signs of pregnancy complications such as mild preclampsia, HELLP and IUGR were detected. TA was started within 24 hours of atrioventricular heart block, 9/20 (45%) with 3rd degree AVB and one (5%) with sinus bradycardia due to other causes (4 age related macular degeneration and 1 vitromacular atrophy due to other causes (4 age related macular degeneration and 1 vitromacular adhesion). Since the discrimination of macular pathology would not be possible with immunosuppression in these patients, HCQ was not prescribed due to the lack of evidence-based guidelines and the alleged risk of maternal and/or fetal adverse events, there is general resistance to its application during pregnancy.

Conclusion: In this observational study we aimed to evaluate the efficacy and safety of TA in high-risk pregnancies in patients with rheumatic diseases, followed over a decade in a tertiary Center.

Background: Therapeutic apheresis (TA) represents a therapeutic option in pre-existing conditions or rheumatic diseases that occur during gestation. Although pregnancy does not alter the disease itself, it often represents a crescendo of disease activity, demands appropriate management, and presents a challenge to assessing the role of apheresis in this setting.

Methods: We retrospectively analyzed patients with biopsy-proven lupus nephritis, who clinically showed RPGN, and were treated by multitarget therapy with tacrolimus and MMF in our department. Data were expressed as means±SD.

Results: Five lupus nephritis patients (3 female) with RPGN were treated by multitarget therapy with tacrolimus and MMF in our department. Data were expressed as means±SD.

Methods: We retrospectively analyzed patients with biopsy-proven lupus nephritis, who clinically showed RPGN, and were treated by multitarget therapy with tacrolimus and MMF in our department. Data were expressed as means±SD.

Results: Five lupus nephritis patients (3 female) with RPGN were treated by multitarget therapy as induction therapy. Mean age was 36.6±13.5 years old. Renal biopsy at treatment revealed Class IV(A) in 2, Class IV(A+C) in 1 and Class IV(A+V) in 2. The mean activity of glomerular crescents was 23.1±25.4%. eGFR and proteinuria at the initiation of treatment were 46.8±11.5mL/min/1.73m² and 7.7±3.4g/gCr, respectively. Patients were initially treated with methylprednisolone pulse therapy followed by 0.8-1.0mg/kg/day of prednisolone (PSL), 2-3mg/day of tacrolimus and 1000mg/day of MMF. At 6 months, eGFR and proteinuria improved to 72.9±11.3mL/min/1.73m² and 0.19±0.39g/L, respectively. At 12 months, eGFR and proteinuria further improved to 76.8±7.8mL/min/1.73m² and 0.10±0.07g/L, respectively and the dose of PSL was reduced to 0.6±0.5mg/day. Three patients became positive for cytomegalovirus antigenemia and were successfully treated with antiviral therapy.

Conclusion: Multitarget therapy is effective in lupus nephritis even in patients pre-treated with RPGN.


Disclosure of Interests: Y. Imai1, H. Ikeuchi1, J. Suwa1, Y. Ohishi1, M. Watanabe1, M. Nakasatomi1, A. Güll1, M. Inanc1, M. L. Ocál1, B. Artim-Esên1, Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey; Istanbul University, Istanbul Faculty of Medicine, Dept of Rheumatology, Istanbul, Turkey; Istanbul University, Istanbul Faculty of Medicine, Dept of Internal Medicine, Istanbul, Turkey; Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Background: Hydroxychloroquine (HCQ) is an immunomodulatory drug that has been shown to improve disease activity in systemic lupus erythematosus (SLE). However, retinal toxicity is an important concern.

Objectives: In this study we sought to evaluate the effect of HCQ on disease activity and damage in patients with SLE in whom HCQ was discontinued due to retinal toxicity and whether it could be restarted by a detailed ophthalmologic examination.

Methods: Patients who met SLE SLICC classification criteria and were on HCQ for at least 3 years after reaching Lupus Low Disease Activity State (LLDAS) following remission induction and were followed up for at least 3 years after termination of HCQ treatment due to retinal toxicity diagnosed with visual field test were analyzed. Disease activity (LLDAS and SLEDAI-2K) and the number and severity of flares were recorded for each patient whilst on HCQ and after cessation of treatment. All patients were examined by two experienced ophthalmologists and were assessed by computerized visual field, optical coherence tomography (OCT), fundus autofluorescence (FAF) and fundus fluorescein angiography (FFA) to further analyze toxicity.

Results: Out of 88 patients with recorded HCQ retinal toxicity in a cohort of 1500 patients with SLE, 64 patients (mean age at diagnosis 33.4 ± 10.5 (10-57); 88.5% female) with complete data and ophthalmologic re-examination results were included in the analyses. The average duration on HCQ was 122 ±85 (39-336) months, and the mean follow-up time was 74.6 ± 48.3 (36-239) months after the drug was discontinued. Comparison of mean disease activity in the 3-year period when patients were on HCQ to 3 years post-cessation revealed a significantly lower mean SLEDAI score (p<0.001) at 12 months vs. 13.1±6.0 vs. 0.024 respectively). There were more patients with serious flares in the post-discontinuation period but without statistical significance (13.1% vs. 4.9% p=0.08). Thirty-seven (60%) of patients restarted the treatment after ophthalmologic examination. Although 38 (62.3%) patients had visual field defects in the latest examination, multimodal imaging with OCT, FAF and FFA revealed that only 19 (31%) patients had typical retinal toxicity. Five patients were found to have macular atrophy due to other causes (4 age related macular degeneration and 1 vitromacular adhesion). Since the discrimination of macular pathology would not be possible with imaging in these patients, HCQ was not prescribed. Comparison of patients with and without retinal toxicity showed that duration of HCQ use and HCQ-free time was not significantly different between patients.

Conclusion: HCQ is effective in controlling disease activity in patients with SLE and an opportunity for re-medication with HCQ is valuable. More than half of the
patients being able to restart HCQ after ophthalmologic examination in this study shows that it is important to perform multimodal imaging techniques in patients with retinal toxicity diagnosis. Since macular pathology can have a different etiologic background, an initial ophthalmologic examination is also necessary. Lack of difference in the duration of HCQ exposure and drug-free time between patients who restarted treatment and who could not may be a sign of personal sensitivity to HCQ toxicity.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6198

SAT0179

ADHESION TO HYDROXYCHLOROQUINE INFLUENCES THE INCIDENCE OF ORGAN DAMAGE FOLLOWING UP IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

J. H. Kang1, S. E. Choi1, H. Xu1, D. J. Park1, S. S. Lee1, 1Chonnam National University Medical School & Hospital, Gwangju, Korea, Rep. of (South Korea)

Background: Objectives: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This study investigated the effects of HCQ adherence on clinical manifestations, disease activity, and organ damage in Korean patients with SLE.

Methods: Data on 299 SLE patients were obtained from the Korean Lupus Network registry. Demographic variables, clinical manifestations, laboratory findings, PGA, and SLEDAI-2000 and SLICC damage index scores were recorded at the time of enrollment and drug-free time between patients with good HCQ adherence during the follow-up period. Patients with poor HCQ adherence were older (P=0.011), less insured (P=0.024), experienced lower employment (P=0.033), and had a higher rate of comorbidities such as hypertension (P=0.048) and depression (P<0.001). The non-adherent group had higher mean and changed SLICC damage index scores than the adherent group across all 4 years. In the multivariate analysis, HCQ non-adherence was significantly associated with older age (OR, 1.043; 95% CI, 1.006–1.081; P=0.021), depression (OR, 1.198; 95% CI, 1.099–1.306; P=0.042), and an annual increase in the SLICC damage index score (OR, 2.275; 95% CI, 1.369–3.779; P<0.002).

Conclusion: HCQ adherence might be influenced by age and depressive mood. Additionally, the poor adherence to HCQ in SLE patients was correlated with higher cumulative organ damage. Therefore, patients with SLE should be educated to take HCQ appropriately to improve their clinical outcome in clinical practice.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1656

SAT0180

ANTIMALARIAL DRUGS ASSOCIATED RETINOPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS

X. F. Largo Rojas1, A. Crespo Golmar1, C. Moriano1, A. López Robles1, E. Díez Álvarez1, T. Pérez Sandoval1, 1Hospital Universitario de León, Rheumatology, León, Spain

Background: The antimalarials remain to be the main treatment for Systemic Lupus Erythematosus (SLE). Its most important limitation when you want to increase dose or remain using them is the occurrence of retinal toxicity, which appears in a small number of patients. Since the lesions can progress even with dose readjustment should be considered in patients with a period of treatment of more than 10 years. In the group treated with CQ none were above the global recommended dose (460g). Of the 3 patients that took both drugs, two were above the recommended dose for HCQ.

25% of the patients had CKD and 10% liver failure, 20% of the patients were active smokers and 15% ex-smokers.

10% of the sample had previous retinopathy related with other comorbidities (age related retinopathy and diabetes), associating hypertension and diabetes mellitus in the same percentage (15%).

Severe retinopathy was found in 1 patient (5%), mild-moderate in 9 patients (45%), retinopathy stages were not specified in 10 patients (50%).

Conclusion: In our sample we observed a prevalence of antimalarials retinopathy of 4.57%, similar of what is found in the literature. Half of the patients had retinopathy in a period of treatment ≤ 5 years, being a described risk factor the duration of treatment of more than 6 years. This early manifestation could be related to the presence of other comorbidities like hypertension, diabetes and CKD.

Dose readjustment should be considered in patients with a period of treatment of more than 10 years. Age seems to be an associated factor for the development of antimalarials retinopathy and to perform a screening in the first year of treatment is important to rule out basal disease related with more risk to develop ocular toxicity.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5996

SAT0181

ALTERATIONS OF PERIPHERAL LYMPHOCYTE SUBSETS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR CHANGES AFTER OUR NEW IMMUNOREGULATORY COMBINATION THERAPIES

J. Q. Zhang1, S. X. Zhang1, L. Xue2, J. Qiao1, M. T. Qiu1, R. Zhao1, M. J. Chang1, Y. Li1, J. Luo1, G. Y. Liu1, C. Gao2, X. Li3, 1The Second Hospital of Shanxi Medical University, Rheumatology, Taiyuan, China; 2The Second Hospital of Shanxi Medical University, Rheumatology, Taiyuan, China; 3Bingham and Women's Hospital, Harvard Medical School, Boston, United States of America

Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by abnormal activation of circulating lymphocytes and overproduction of autoantibodies. Breakdown of self-tolerance is considered as a critical cause in the development of SLE. However, the quantitative changes of lymphocyte subsets in SLE are unclear. Since low-dose IL-2 and several drugs have been used to promote the proliferation of regulatory T cells (Tregs), we developed immunoregulatory therapies using these drugs to rebalance effector T cells with Tregs and test whether they are benefit to remission disease activity of SLE.

Objectives: To observe the different levels of peripheral lymphocyte subsets at the first laboratory examination of SLE patients with those of healthy controls (HCs) and to evaluate the effect of immunoregulatory combination therapies on levels of lymphocyte subsets in patients with SLE.

Methods: From September 2014 to December 2019, a total of 985 diagnosed patients with SLE (878 females, 107 males, mean age 42.9±13.37 years) and 206 healthy adults were enrolled in this retrospective cross-sectional study. And 795 patients with SLE (711 females and 84 males, mean age 38.26±15.242 years) were received the immunomodulatory drugs (IMDs) such as low-dose interleukin-2, rapamycin, metformin, retinoic acid, coenzymes Q10 or other immunomodulatory treatments. The absolute numbers of T, B, NK, CD4+T, CD8+T, Th1, Th2, Th17 and CD4+CD25+FoxP3+ regulatory cells (Tregs) in peripheral blood (PB) of these individuals were measured by Flow Cytometer (FCM) combined with standard absolute counting beads.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6198

Saturday, 06 June 2020

1031